Xia Yiping, CEO of Extreme Vietnam: I am only a minority shareholder of the company, and Baidu has 80% of the voting rights. I learned from employees inside Extreme Vietnam that Xia Yiping, CEO of Extreme Vietnam, communicated with employee representatives about the company this afternoon. He revealed that the board of directors had a meeting the night before the 11th solution was released, and no agreement was reached on employee social security. It is not up to you to decide the plan that is released only after you get the resolution from the board of directors. "I said that I could take some money to solve the social security problem of employees, but in this case, neither shareholder stood up." He said that he is the CEO of the company, but he is only a minority shareholder and has decision-making power in business, but he has no decision-making power in the development of the company and needs the decision of the board of directors. 80% of the voting rights of the company are in Baidu. Baidu has just conducted a comprehensive audit of the company recently, and there are no problems. (Sina Technology)The tenth batch of national procurement officially opened, and the number of enterprises and varieties involved reached a record high. The tenth batch of centralized drug procurement organized by the state officially accepted the application materials of enterprises at 8: 00 this morning at No.398 Zhanyuan Road, Nanqiao New Town, Fengxian District, Shanghai. This centralized procurement involved 62 varieties and 263 product specifications, and the number of enterprises and varieties involved reached a record high. Among them, 33 enterprises competed for nine short-listed oral sustained-release formulations of sitagliptin. There are also a number of varieties that are billions in the market of public hospitals, such as doxorubicin hydrochloride liposome injection, cefoperazone injection, piperacillin injection, compound α -ketoacid oral sustained-release dosage form, norepinephrine injection and aspirin oral sustained-release dosage form. The sales scale in sample hospitals last year all exceeded 2 billion yuan. Hengrui Pharma, Kelun Pharmaceutical, Unacon and Zhengda Tianqing participated with many varieties. Note: According to the tenth batch of national adoption documents released before, the tenth batch of national adoption rules have changed a lot, such as canceling the protection mechanism of 50% price reduction and increasing the fuse recovery mechanism by 1.8 times, and the number of B-certified enterprises affects the number of final finalists.Commander-in-Chief of Russian Navy: NATO increases its military activities in the Arctic.
Huazhi Liquor Store: It is planned to distribute a cash dividend of 8.09 yuan for every 10 shares. Huazhi Liquor Store announced that the company's profit distribution plan for the first three quarters of 2024 has been approved by the shareholders' meeting. The company will distribute a cash dividend of RMB 8.09 to all shareholders for every 10 shares based on the existing total share capital of 417 million shares and the share capital of 408 million shares after 9,098,100 shares have been repurchased in the repurchase special securities account. The total amount of cash dividends actually distributed was 330 million. The distribution of rights and interests in date of record is December 19th, 2024, and the ex-dividend date is December 20th, 2024. This dividend does not involve bonus shares and capitalization of capital reserve.Yin Zhongyu, Federal Reserve Securities: Industrial M&A will always have the opportunity to cross-border M&A and will never be supported on a large scale. Yin Zhongyu, assistant to the president of Federal Reserve Securities and head of the M&A business department, pointed out that M&A has ushered in a rare policy window. For industrial M&A, the policy window has always been there. "In particular, industrial M&A focusing on new productivity has always been the direction encouraged by the regulatory authorities, and there will always be opportunities. However, for buying and selling shells and cross-border restructuring, related risks need to be vigilant, and cross- (21 Finance)Jianfan Bio: The plasma separator was certified by the European Union MDR, and Jianfan Bio announced that Jianfan Blood Purification Company, a wholly-owned subsidiary, recently received a notice from the EU announcement agency that its plasma separator was certified by the European Union MDR in accordance with the EU Medical Devices Regulation 2017/745, and can be sold in EU countries and other countries that recognize the EU CE certification.
CITIC Securities: The resonance between supply and demand of medical beauty accelerates the space expansion, and the difference in operating ability promotes the evolution of the industry structure. CITIC Securities Research Report stated that the medical beauty industry has both medical and consumption attributes, and the medical attribute has strong product-driven characteristics, while the consumption attribute has high operating ability requirements. The medical beauty botulinum toxin track is also affected by the dual attributes of medicine and consumption: 1) The increase in penetration rate, the acceleration of compliance substitution and the extension of indications have brought about high demand for medical beauty botulinum toxin, and with the recent supply expansion, the industry scale has experienced high growth; 2) The iteration of product innovation is slow, brand barriers are created through marketing, doctors are empowered through direct sales, and control is strengthened to enhance product competitiveness. Recently, a variety of medical botulinum toxins in China have been approved, and the promotion of low-priced products is expected to push up the penetration rate, and enterprises with strong operational capabilities will enter the market or promote the evolution of the pattern.Tongfu Microelectronics traded 2.24 million shares at a discount of 60.0768 million yuan today. Tongfu Microelectronics traded 2.24 million shares at a discount of 60.0768 million yuan today, accounting for 3.32% of the total turnover of the day, and the transaction price was 26.82 yuan, which was 9.97% lower than the market closing price of 29.79 yuan.US President-elect Trump: Opposing Ukrainian armed forces to attack Russia with US long-range missiles has further escalated the conflict.
Strategy guide
12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14